Psychosis from a Bath Salt Product Containing Flephedrone and MDPV with Serum, Urine, and Product Quantification

Journal of Medical Toxicology

Volumn 8, Issue 3, 2012, Pages 310-313

  Thornton, Stephen L ^a,b   Gerona, Roy R ^c   Tomaszewski, Christian A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Flephedrone; MDPV; Psychosis; Synthetic cathinones

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; 4 FLUOROMETHCATHINONE; BATH SALT; CATHINONE; COSMETIC; DROPERIDOL; LORAZEPAM; UNCLASSIFIED DRUG;

ABNORMAL BEHAVIOR; ADULT; AERATION; ARTICLE; AUDITORY HALLUCINATION; BIPOLAR DISORDER; BLOOD LEVEL; CASE REPORT; CHEMICAL ANALYSIS; CONCENTRATION (PARAMETERS); DIAPHORESIS; DIFFERENTIAL DIAGNOSIS; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; HALLUCINATION; HUMAN; INTOXICATION; LIQUID CHROMATOGRAPHY; MALE; MEDICAL HISTORY; MYDRIASIS; OBSERVATION; PHYSICAL EXAMINATION; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; QUANTITATIVE ANALYSIS; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SUICIDAL BEHAVIOR; TACHYCARDIA; TACTILE HALLUCINATION; TIME OF FLIGHT MASS SPECTROMETRY; TOXICITY TESTING; URINE LEVEL; VISUAL HALLUCINATION;

ALKALOIDS; BENZODIOXOLES; DESIGNER DRUGS; DROPERIDOL; HUMANS; INSUFFLATION; LORAZEPAM; MALE; PROPIOPHENONES; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; PYRROLIDINES; SALTS; YOUNG ADULT;

EID: 84865737058     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-012-0232-4     Document Type: Article

References (17)

1. Centers for Disease Control and Prevention (CDC) (2011) Emergency department visits after use of a drug sold as "bath salts"-Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep 60(19): 624-627.
2. Spiller HA, Ryan ML, Weston RG et al (2011) Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol (Phila) 49(6): 499-505.
3. Reitzel LA, Dalsgaard PW, Müller IB, et al. (2012) Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish Internet company. Drug Test Anal (in press).
4. Antonowicz JL, Metzger AK, Ramanujam SL (2011) Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry 33(6): 640.
5. Spencer JW, Long C, Scalzo AJ et al (2011) Acute psychiatric, cardiopulmonary, and neurologic effects of laboratory-confirmed use of methylenedioxypyrovalerone (MDPV) "bath salts". (Abstract). Clin Toxicol (Phila) 49: 515-627.
6. Lung DD, Gerona RR, Wu AH, et al (2012) Confirmed glyburide poisoning from ingestion of "Street Valium". J Emerg Med (in press).
7. Bunker ML, McWilliams M (1979) Caffeine content of common beverages. J Am Diet Assoc 74(1): 28-32.
8. Morefield KM, Keane M, Felgate P et al (2011) Pill content, dose and resulting plasma concentrations of 3, 4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. Addiction 106(7): 1293-1300.
9. Brandt SD, Sumnall HR, Measham F et al (2010) Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal 2(8): 377-382.
10. Drug Enforcement Administration (DEA) (2011) Department of Justice. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final order. Fed Regist 76(204): 65371-65375.
11. Yubero-Lahoz S, Ayestas MA Jr, Blough BE et al (2012) Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain. Eur J Pharmacol 674(2-3): 337-344.
12. Mugele J, Nañagas KA, Tormoehlen LM (2012) Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med (in press).
13. Hadlock GC, Webb KM, McFadden LM et al (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339(2): 530-536.
14. Murray BL, Murphy CM, Beuhler MC (2012) Death following recreational use of designer drug "bath salts" containing 3, 4-methylenedioxypyrovalerone (MDPV). J Med Toxicol 8(1): 69-75.
15. Fuller RW (1978) Structure-activity relationships among the halogenated amphetamines. Ann N Y Acad Sci 305: 147-159.
16. Meyer MR, Du P, Schuster F et al (2010) Studies on the metabolism of the α pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 45(12): 1426-1442.
17. Pawlik E, Plässer G, Mahler H et al (2012) Studies on the phase I metabolism of the new designer drug 3-fluoromethcathinone using rabbit liver slices. Int J Legal Med 26: 231-240.